There are 169 resources available
Statistical and study design considerations for dose-finding and dose optimisation in early-phase oncology trials
Presenter: Pavel Mozgunov
Session: The quest for dosage and combination optimisation in early drug development
Resources:
Slides
Webcast
Is there a role for biomarker selection for CDK4/6 inhibitors?
Presenter: Stacy Moulder
Session: Next generation cell cycle inhibitors and role of biomarker selection
Resources:
Slides
Webcast
Project Optimus: FDA’s implementation of the (draft) guidance in practice and implications for drug developers
Presenter: Sinan Sarac
Session: The quest for dosage and combination optimisation in early drug development
Resources:
Slides
Webcast
Targeting resistance to CDK4/6 cell cycle inhibitors
Presenter: Geoffrey Shapiro
Session: Next generation cell cycle inhibitors and role of biomarker selection
Resources:
Slides
Webcast
Practical approaches to perform dose and combination optimisation in early phase trials, from academic/cooperative group perspective
Presenter: Stefan Symeonides
Session: The quest for dosage and combination optimisation in early drug development
Resources:
Slides
Webcast
Use of ctDNA for the management of patients on CDK4/6 inhibitors
Presenter: Nicholas Turner
Session: Next generation cell cycle inhibitors and role of biomarker selection
Resources:
Slides
Webcast
Role of pharmacogenomics, pharmacokinetics, and pharmacodynamics for dose optimisation in oncology drug development
Presenter: George P. Patrinos
Session: The quest for dosage and combination optimisation in early drug development
Resources:
Slides
Webcast
Panel discussion
Presenter: All Speakers
Session: The quest for dosage and combination optimisation in early drug development
Resources:
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Next generation cell cycle inhibitors and role of biomarker selection
Resources:
Webcast
What should pharmacology tell us before moving a drug from bench to bedside?
Presenter: Sander Bins
Session: What data I need from the lab before running a phase I
Resources:
Slides
Webcast